Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$31.93 ▲ +0.20
(+0.63%)
MKT CAP: $1.77B • VOL: 417.9K
52W L $22 52W H $54
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
MAZE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $167.5M |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$142.9M | $57.6M |
| Operating Margin % | — | 34.4% |
| Net Income (GAAP) | -$131.1M | $52.2M |
| EBITDA (Normalized) | -$142.3M | $58.5M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$111.9M | $76.0M |
| Capital Expenditures (CapEx) | $794.0K | $1.1M |
| Free Cash Flow (FCF) | -$112.7M | $74.8M |
| FCF Margin % | — | 44.7% |
| Return on Invested Capital (ROIC %) | -45.0% | 95.0% |
| Cash & Short-Term Equivalents | $189.2M | $196.8M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $355.0M | -$311.2M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MAZE.